호흡기 바이러스 백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Respiratory Virus Vaccines Market size is expected to reach USD 22.22 Billion in 2034 from USD 10.82 Billion (2025) growing at a CAGR of 8.32% during 2026-2034.

The global respiratory virus vaccines market has experienced significant growth, especially following the COVID-19 pandemic, which highlighted the importance of immunization against respiratory infections. Vaccines targeting influenza, respiratory syncytial virus (RSV), and coronaviruses are increasingly in demand. Governments and healthcare organizations are prioritizing vaccination programs, leading to higher adoption rates and expanded immunization coverage worldwide.

Major growth drivers include rising incidences of respiratory infections, increased public awareness, and advancements in vaccine technologies such as mRNA and recombinant platforms. Pharmaceutical companies are focusing on developing combination vaccines that provide protection against multiple respiratory viruses. Additionally, seasonal outbreaks and pandemic preparedness initiatives are encouraging continuous investment in vaccine research and production capabilities.

In the future, the market is poised for robust expansion due to ongoing innovation and global vaccination strategies. The development of universal vaccines and needle-free delivery systems is expected to enhance convenience and compliance. Expanding healthcare access in developing countries and increasing government funding will further drive growth, ensuring better protection against emerging and existing respiratory viruses.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Inactivated/Killed
• Live-attenuated
• Recombinant

By Route of Administration

• Intramuscular
• Intranasal
• Subcutaneous

By Indication

• Influenza
• Measles
• Mumps & Rubella
• Coronavirus Disease (COVID-19)

By Age Group

• Pediatric
• Adults

By End User

• Physician Offices
• Hospitals
• Clinics
• Pharmacies/Stores

COMPANIES PROFILED

• Sanofi, AstraZeneca, Merck Co Inc, GlaxoSmithKline PLC, Serum Institute of India Pvt Ltd, Moderna Inc, Bavarian Nordic, SINOVAC, INOVIO Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Inactivated/Killed Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Live-attenuated Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Recombinant Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Intranasal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY INDICATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Measles Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Mumps & Rubella Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.5. Coronavirus Disease (COVID-19) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY END USER 2022-2034 (USD MN and Million Doses)

• 8.1. Market Analysis, Insights and Forecast End User
• 8.2. Physician Offices Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 8.5. Pharmacies/Stores Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL RESPIRATORY VIRUS VACCINES MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.2.1 By Type
  • 9.2.2 By Route Of Administration
  • 9.2.3 By Indication
  • 9.2.4 By Age Group
  • 9.2.5 By End User
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.3.1 By Type
  • 9.3.2 By Route Of Administration
  • 9.3.3 By Indication
  • 9.3.4 By Age Group
  • 9.3.5 By End User
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.4.1 By Type
  • 9.4.2 By Route Of Administration
  • 9.4.3 By Indication
  • 9.4.4 By Age Group
  • 9.4.5 By End User
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.5.1 By Type
  • 9.5.2 By Route Of Administration
  • 9.5.3 By Indication
  • 9.5.4 By Age Group
  • 9.5.5 By End User
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 9.6.1 By Type
  • 9.6.2 By Route Of Administration
  • 9.6.3 By Indication
  • 9.6.4 By Age Group
  • 9.6.5 By End User
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL RESPIRATORY VIRUS VACCINES INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Sanofi
  • 11.2.2 AstraZeneca
  • 11.2.3 Merck & Co. Inc
  • 11.2.4 GlaxoSmithKline PLC
  • 11.2.5 Serum Institute Of India Pvt. Ltd
  • 11.2.6 Moderna Inc
  • 11.2.7 Bavarian Nordic
  • 11.2.8 SINOVAC
  • 11.2.9 INOVIO Pharmaceuticals